Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock
March 30 2021 - 8:08PM
Business Wire
Humanigen, Inc. (Nasdaq:HGEN)
(“Humanigen”), a clinical stage biopharmaceutical company focused
on preventing and treating an immune hyper-response called
“cytokine storm” with its lead drug candidate lenzilumab™, today
announced that it has priced its underwritten public offering of
5,000,000 shares of its common stock at a public offering price of
$18.50 per share, resulting in gross proceeds to Humanigen of
approximately $92.5 million, before deducting underwriting
discounts and commissions and offering expenses. The offering is
expected to close on or about April 5, 2021. Humanigen also granted
the underwriters a 30-day option to purchase up to an additional
750,000 shares at the public offering price, less underwriting
discounts and commissions.
Jefferies, Credit Suisse and Cantor are acting as joint
book-running managers for the offering. Bryan, Garnier & Co. is
acting as European lead manager for the offering, Oppenheimer &
Co. is acting as lead manager for the offering and H.C. Wainwright
& Co., National Securities Corporation and Roth Capital
Partners are acting as co-managers for the offering.
Humanigen intends to use the net proceeds from the offering for
manufacturing and commercial preparation in the event of receipt of
an Emergency Use Authorization from the Food and Drug
Administration for lenzilumab™ in hospitalized COVID-19 patients,
as well as for working capital and other general corporate
purposes.
A registration statement relating to the securities being sold
in the offering has been declared effective by the Securities and
Exchange Commission (the “SEC”). The securities will be offered
only by means of a prospectus supplement and accompanying
prospectus forming a part of the effective registration statement.
A preliminary prospectus supplement relating to and describing the
terms of the offering has been filed with the SEC and is available
on the SEC’s website located at www.sec.gov. Copies of the
prospectus supplement and the accompanying prospectus relating to
and describing the terms of the offering may be obtained, when
available, from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by e-mail at prospectus_department@jefferies.com or by
telephone at (877) 821-7388; Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, North Carolina 27650, by email at
usa.prospectus@credit-suisse.com or by telephone at (800) 221-1037;
or Cantor Fitzgerald & Co., Attention: Capital Markets, 499
Park Ave., 6th Floor, New York, New York 10022, by e-mail at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of any securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements.
Forward-looking statements reflect management’s current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
“will,” “expect,” “intend,” “plan,” “potential,” “possible,”
“goals,” “accelerate,” “continue,” and similar expressions identify
forward-looking statements. Examples of forward-looking statements
in this release include, without limitation, statements regarding
the timing for completing the offering, and the amount and
contemplated use of proceeds from the offering. Forward-looking
statements are subject to a number of risks and uncertainties
including, but not limited to, the various risks and uncertainties
described in the “Risk Factors” sections and elsewhere in the
Company's periodic and other filings with the Securities and
Exchange Commission. All forward-looking statements are expressly
qualified in their entirety by this cautionary notice. You should
not place undue reliance on any forward-looking statements, which
speak only as of the date of this release. We undertake no
obligation to revise or update any forward-looking statements made
in this press release to reflect events or circumstances after the
date hereof or to reflect new information or the occurrence of
unanticipated events, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210330006129/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563
Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024